Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy.
Vogel MME, Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Mix M, la Fougère C, Eiber M, Christiansen H, Belka C, Grosu AL, Müller AC, Guckenberger M, Combs SE.
Vogel MME, et al. Among authors: guckenberger m.
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2328-2338. doi: 10.1007/s00259-020-04760-8. Epub 2020 Mar 16.
Eur J Nucl Med Mol Imaging. 2020.
PMID: 32179961
Free PMC article.